Take a look at Cist: Their book value is almost 2x their market cap... they own the patents on IL1b and have a potential 30 million dollar vaccine deal.
Cistron One of First Biotechnology Companies to Use Internet to Merge or Sell Or to License Its Technology
PINE BROOK, N.J., June 23 /PRNewswire/ -- One of the first attempts on the Internet to sell a publicly traded biotechnology company has been made by Cistron Biotechnology, Inc.'s (OTC: CIST - news) investment banker, Genome Securities, Inc. at
On the web site, Cistron is offered as a business available for sale, merger or acquisition. Another option provides for the licensing of Cistron's intellectual property rights by other companies. Genome Securities expects to receive proposals between now and August 31.
The web site shows Cistron as having a strong cash position and owning the intellectual property rights to Interleukin 1 (IL-lb),
a monoclonal antibody with potential in the treatment of rheumatoid arthritis and other therapeutic
applications. The biotechnology company is also a partner with Pasteur Merieux Connaught in determining the use of IL-lb in vaccine adjuvants, a relationship that could yield $31 million to Cistron in milestone payments and royalties.
Robert W. Naismith, Genome Securities' CEO stated, ``It is apparent that small cap companies require innovation in
developing interest in their technology. Electronic commerce allows an entirely new marketing paradigm and distribution opportunity. In an attempt to maximize the value of Cistron's technology and to provide for the widest possible exposure, we are proffering the company on the Internet. We plan on following this with targeted e-mail inviting the life science company
business development professionals to visit our website to review the opportunity.''